Guggenheim Downgrades Global Blood Therapeutics (GBT) to Neutral
Tweet
Share
E-mailGet Alerts GBT Hot Sheet
Price: $68.49 --0%
Rating Summary:
12 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 15 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja downgraded Global Blood Therapeutics (NASDAQ: GBT) from Buy to Neutral with a price target of $68.50.
For an analyst ratings summary and ratings history on Global Blood Therapeutics click here. For more ratings news on Global Blood Therapeutics click here.
Shares of Global Blood Therapeutics closed at $63.84 yesterday.
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
- Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
